Assembly Bio releases corporate deck highlighting clinical-stage pipeline, Gilead-partnered HSV program
ASMB•Cash runway projected into 2029
Cash runway is projected into 2029, supported by about $320.4 million cash at June 30, 2026, with a $75 million collaboration payment due in 4Q 2026.
Corporate deck outlines pipeline timelines
Assembly Biosciences outlined three Phase 2 starts across its portfolio in late 2026 to early 2027, with key data readouts in 2027-2028.
- ABI-6250 Phase 2 in hepatitis D targeted for 4Q 2026, with data expected in 4Q 2027.
- A separate ABI-6250 Phase 2 in primary biliary cholangitis or primary sclerosing cholangitis targeted for 1Q 2027, with data expected in 1H 2028.
- Gilead-selected HSV candidate GS-1179 is slated for Phase 2 in recurrent genital herpes in 4Q 2026 under the companies’ collaboration.
